Word

S

Status

Pending

Status Code

730

Status Date

Thursday, April 11, 2024

Serial Number

97187298

Mark Type

3000

Filing Date

Thursday, December 23, 2021

Published for Opposition

Tuesday, August 22, 2023

Trademark Owner History

SwanBio Therapeutics Limited - Owner At Publication

Classifications

5 Therapeutic pharmaceutical compositions comprised of adeno-associated viral (AAV) vectors and recombinant adeno-associated viral (rAAV) vectors for therapeutic effect in gene therapy, namely, gene inhibition therapy and/or RNA interference (RNAi), for the treatment of genetic diseases and disorders and neurological diseases and disorders; therapeutic pharmaceutical compositions comprised of adeno-associated viral (AAV) vectors and recombinant adeno-associated viral (rAAV) vectors for therapeutic effect in gene therapy, namely, gene augmentation therapy, for the treatment of genetic diseases and disorders and neurological diseases and disorders; therapeutic pharmaceutical compositions comprised of adeno-associated viral (AAV) vectors and recombinant adeno-associated viral (rAAV) vectors for therapeutic effect in gene therapies using intrathecal administration, for the treatment of genetic diseases and disorders and neurological diseases and disorders; biologic preparations for use in the treatment of genetically based diseases and disorders; biologic preparations for medical purposes, namely, for gene therapy for treating genetic disorders; pharmaceutical preparations that modulate RNA expression for the treatment of neurological diseases and disorders, genetic diseases and disorders, and for the regulation of protein production; gene therapy products, namely, gene delivery pharmaceuticals for the treatment of genetic diseases and disorders and neurological diseases and disorders; pharmaceutical preparations for gene therapy, gene inhibition and gene augmentation, for the treatment of genetic diseases and disorders and neurological diseases and disorders; viruses, viral vectors and viral constructs, all in the nature of pharmaceutical preparations, for the treatment of neurological diseases and disorders and genetic diseases and disorders; pharmaceutical preparations for gene therapy, for the treatment of genetic diseases and disorders and neurological diseases and disorders; pharmaceutical and biopharmaceutical agents for the treatment of genetic disorders and neurological diseases and disorders; pharmaceutical preparations, namely, nucleic acid therapeutics for the treatment of genetic disorders and neurological diseases and disorders; pharmaceutical preparations, namely, DNA and/or RNA therapeutics for the treatment of genetic disorders and neurological diseases and disorders

42 Development of pharmaceutical preparations for use in gene therapy; genetic engineering and biotechnology research; research and development of new products in the field of gene therapeutics; scientific and medical research in the field of genetics, gene therapy and genetic engineering; laboratory research in the fields of genetics, gene therapy, drug development, biotechnology, microbiology and molecular biology; pharmaceutical drug discovery; scientific research in the field of gene therapy discovery; drug development and therapeutic drug development; genetic drug development and therapeutic drug development; biological research; biological drug development and scientific research in the field of biological development

The mark consists of a stylized S in the shape of a swan's wing.

Trademark Events

Apr 11, 2024

Sou Extension 1 Granted

Apr 11, 2024

Sou Extension 1 Filed

Apr 11, 2024

Sou Teas Extension Received

Oct 17, 2023

Noa E-Mailed - Sou Required From Applicant

Aug 22, 2023

Official Gazette Publication Confirmation E-Mailed

Aug 22, 2023

Published For Opposition

Aug 2, 2023

Notification Of Notice Of Publication E-Mailed

Jul 19, 2023

Approved For Pub - Principal Register

Jun 29, 2023

Teas/Email Correspondence Entered

Jun 29, 2023

Correspondence Received In Law Office

Jun 29, 2023

Teas Request For Reconsideration Received

May 19, 2023

Notification Of Final Refusal Emailed

May 19, 2023

Final Refusal E-Mailed

May 19, 2023

Final Refusal Written

Apr 10, 2023

Teas/Email Correspondence Entered

Apr 10, 2023

Correspondence Received In Law Office

Apr 10, 2023

Teas Response To Office Action Received

Oct 12, 2022

Notification Of Non-Final Action E-Mailed

Oct 12, 2022

Non-Final Action E-Mailed

Oct 12, 2022

Non-Final Action Written

Sep 27, 2022

Assigned To Examiner

Jan 15, 2022

Notice Of Design Search Code E-Mailed

Jan 14, 2022

New Application Office Supplied Data Entered